Tempest Therapeutics reports Q2 EPS (54c), consensus (52c)

Tempest ended Q2 with $17.6M in cash and cash equivalents, compared to $31.2M on December 31, 2022. “2023 continues to be a productive and potentially transformative year for Tempest,” said CEO Stephen Brady. “In the second quarter, we presented data from our second clinical program, TPST-1495, the company’s novel dual EP2/EP4 antagonist designed to selectively modulate the prostaglandin pathway, both at ASCO and in a paper published in Cancer Research Communications. These presentations were made on the heels of announcing early exciting triplet data from our lead TPST-1120 program demonstrating a clinically-meaningful improvement over standard of care alone in first-line HCC patients in an ongoing, global, randomized Phase 1b/2 study. We expect to be able to discuss an updated and comprehensive data set from the formal review of this trial in the second half of 2023.”